Pancreatic cancers are often described as heterogeneous and, while in excess of 90% will have activation of KRAS,11 this is invariably accompanied by a wide variety of tumour suppressor losses,12 which may contribute to the variability of clinical response to inhibition of specific pathways. This evidence concerns the gene KRAS and familial pancreatic carcinoma.